TuHURA FY2025 cash $3.6M, R&D $20.5M; Phase 3 MCC trial ongoing; Kineta acquired

TuHURA Biosciences, Inc./NV

Cash $3.6M at Dec 31, 2025; additional $7.5M from 2025 registered direct offering received Q1 2026.
R&D expenses $20.5M for FY2025 vs $14.7M in FY2024; operating cash outflow $27.7M.
Phase 3 trial of IFx-2.0 in Merkel cell carcinoma initiated under FDA SPA; enrollment estimated to complete mid-2027.
Closed $10.5M acquisition of Kineta, gaining VISTA antibody TBS-2025; $21.2M raised in 2025 offerings.
Upcoming milestones: FDA meeting for TBS-2025 in June 2026; ADC lead selection in 1H 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

TuHURA Biosciences, Inc./NV reported financial results for for the Company's fourth quarter and full year ended December 31, 2025.

Period: for the Company's fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TuHURA Biosciences, Inc./NV reported financial results for for the year ended December 31, 2025.

Period: for the year ended December 31, 2025
Result: reported results

Exact text from the filing

On April 1, 2026, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the year ended December 31, 2025, and providing a corporate update.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0001193125-26-135766

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.